Trek Financial’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Trek Financial’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.07M	Buy	+90,940	New	+$2.73M	0.15%	140

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Trek Financial's IDNA Position: Q2 2026 in Review

Trek Financial opened a new position in iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2026: 90,940 shares worth $3.07M. The stake represents 0.15% of the portfolio and ranks #140 among its holdings.

65 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Trek Financial held 90,940 shares of iShares Genomics Immunology and Healthcare ETF worth $3.07M as of Q2 2026.
iShares Genomics Immunology and Healthcare ETF was a new Trek Financial position in Q2 2026.
iShares Genomics Immunology and Healthcare ETF made up 0.15% of Trek Financial's portfolio in Q2 2026, its #140 holding.
65 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Trek Financial's 13F filing for Q2 2026, filed 13 Aug 2026.